Price$17.07+0.71 (+4.37%)
01:30 PM07:45 PM
News · 26 weeks71-67%
2026-01-182026-07-12
Mix4290d
- Insider26(62%)
- Other6(14%)
- SEC Filings5(12%)
- Analyst3(7%)
- Earnings2(5%)
Latest news
25 items- INSIDEREVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 3,636 shares and covered exercise/tax liability with 1,926 shares, increasing direct ownership by 6% to 29,815 units (SEC Form 4) (tax withholding)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- PRTandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International MarketsCompatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2™ insulin pump with Control-IQ+TM automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor in five countries. This launch expands continuous glucose monitoring choice for t:slim X2 pump users in the United Kingdom, Switzerland, Sweden, Finland, and Italy. Tandem expects to add additional countries in 2026, including Belgium, the Netherlands, and Germany."People using AID want fle
- PRTandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI09573d6
- ANALYSTDeutsche Bank initiated coverage on Tandem Diabetes Care with a new price targetDeutsche Bank initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $15.50
- PRTandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During PregnancyTandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery (AID) systems in Europe. The t:slim X2 and Tandem Mobi insulin delivery systems running Control-IQ+ AID technology are now approved for use by people with type 1 diabetes during pregnancy and adults with type 2 diabetes. "These expanded indications underscore the strength of our portfolio and our commitment to bringing innovative diabetes technology to more people worldwide," said John Sheridan, president and chief executive officer. "By expanding access to our AID technology, we're broadening ou
- INSIDEREVP, Chief Strategy Officer Gasser Elizabeth Anne gifted 7,160 shares and received a gift of 7,160 shares, closing all direct ownership in the company (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT & CEO Sheridan John F4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Chief Strategy Officer Gasser Elizabeth Anne4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Operating Officer Kyrillos Jean-Claude4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Legal Officer Hansen Shannon Marie4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Admin. Officer Morrison Susan4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Chief Technology Officer Carpenter Rick4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- ANALYSTTandem Diabetes Care upgraded by Wells Fargo with a new price targetWells Fargo upgraded Tandem Diabetes Care from Equal Weight to Overweight and set a new price target of $27.00
- SECSEC Form SD filed by Tandem Diabetes Care Inc.SD - TANDEM DIABETES CARE INC (0001438133) (Filer)
- SECSEC Form S-8 filed by Tandem Diabetes Care Inc.S-8 - TANDEM DIABETES CARE INC (0001438133) (Filer)
- INSIDERChair Emeritus Allen Dick converted options into 8,759 shares, increasing direct ownership by 45% to 28,146 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Howell Peyton R converted options into 8,759 shares, increasing direct ownership by 42% to 29,836 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Malagueira Joao Paulo Falcao converted options into 8,759 shares, increasing direct ownership by 64% to 22,458 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERSEC Form 4 filed by Director Beaver Sandra4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Mcgroddy-Goetz Kathleen converted options into 8,759 shares, increasing direct ownership by 49% to 26,612 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Sodhi Rajwant converted options into 8,759 shares, increasing direct ownership by 56% to 24,280 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Robertson Rebecca B converted options into 8,759 shares, increasing direct ownership by 64% to 22,542 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Twomey Christopher J converted options into 8,759 shares, increasing direct ownership by 56% to 24,434 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
- INSIDERDirector Cha Myoungil converted options into 8,759 shares, increasing direct ownership by 64% to 22,458 units (SEC Form 4)4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
TNDM FAQ
7 questionsWhat does Tandem Diabetes Care Inc. do?
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a...Where does TNDM stock trade?
Tandem Diabetes Care Inc. (TNDM) is listed on NASDAQ.What sector and industry is TNDM in?
Tandem Diabetes Care Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Tandem Diabetes Care Inc. go public?
Tandem Diabetes Care Inc. (TNDM) completed its IPO in 2013.What are analysts saying about TNDM?
Tandem Diabetes Care Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Hold with a $1550.00 price target on 2026-06-23. Recent price targets range from $1550.00 to $3500.00.What companies are similar to TNDM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare TNDM side-by-side with any of them on Quantisnow.How can I track TNDM on Quantisnow?
Quantisnow aggregates Tandem Diabetes Care Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TNDM to receive live email and push alerts on every new disclosure.